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ABSTRACT 
 
Evaluation of Sindbis-M2e Virus Vector as a Universal Influenza A Vaccine.  
(August 2012) 
Christine Nguyen Vuong, 
B.S., Texas A&M University 
Chair of Advisory Committee: Dr. Blanca M. Lupiani 
 
 Although avian influenza virus (AIV) infections in domestic poultry are 
uncommon, transmission of avian influenza from wild waterfowl reservoirs does occur.  
Depopulation of the infected flock is the typical response to AIV outbreaks in domestic 
chicken production, causing a loss in profits and accumulation of unexpected expenses.  
Because it is impossible to know which of many virus subtypes will cause an outbreak, 
it is not feasible for the U.S. to stockpile vaccines against all possible avian influenza 
threats.  Currently, the U.S. does not routinely vaccinate chickens against influenza due 
to the inability to differentiate infected from vaccinated animals (DIVA), which would 
place limitations on its trade markets.  A Sindbis virus vector expressing the PR8 
influenza strain’s M2e peptide was developed as a potential universal DIVA vaccine.  
M2e is a conserved peptide amongst influenza A viruses; M2e-specific antibodies 
induce antibody-dependent cytotoxicity or phagocytosis of infected cells, reducing 
production and shedding of AIV during infection.  In this study, chickens were 
vaccinated at one-month-of-age with parental (E2S1) or recombinant Sindbis viruses 
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expressing the PR8 M2e peptide (E2S1-M2e) by subcutaneous or intranasal routes at 
high (106 pfu) or low (103 pfu) dosages.  Chickens were boosted at 2-weeks post-initial 
vaccination using the same virus, route, and dosage, then challenged with low 
pathogenic H5N3 AIV at 0.2 mL of 106/mL EID50 2-weeks post-boost.  Serum samples 
were collected at 1-week and 2-weeks post-vaccination, 2-weeks post-boost, and 2-
weeks post-challenge and screened for PR8 M2e-specific IgY antibody production by 
ELISA.  Both high and low dose subcutaneously, as well as high dose intranasally 
vaccinated E2S1-M2e groups produced significantly higher levels of PR8 M2e-specific 
IgY antibodies as early as 1-week post-vaccination, while the uninoculated control and 
E2S1 groups remained negative for all pre-challenge time points.  M2e-specific IgY 
antibodies capable of binding the challenge H5N3 M2e peptide were detected in groups 
with existing vaccine-induced M2e-specific antibodies pre-challenge, suggesting 
antibody M2e cross-reactivity.  After challenge, all groups developed M2e-specific IgY 
antibodies and high HI titers, verifying successful AIV infection during challenge and 
production of hemagglutinin-specific antibodies.  Viral shedding titers 4-days post-
challenge were used to measure vaccine efficacy and were similar amongst all groups.  
Microneutralization assay results confirmed that post-boost serum samples, containing 
only M2e-specific antibodies, were unable to neutralize AIV in vitro.  Although the 
E2S1-M2e vaccine was capable of producing high levels of M2e-specific IgY 
antibodies when inoculated subcutaneously, these antibodies were not able to reduce 
viral shedding and therefore did not protect chickens from AIV.   
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1. INTRODUCTION 
1.1. Avian influenza virus 
 Avian influenza virus (AIV) was originally described in northern Italy as “fowl 
plague” by Edward Perroncito during an outbreak in poultry, confusing the disease with 
an acute septicemic form of avian cholera (2, 15, 84, 100).  Based on clinical and 
pathological properties, the disease was shown to be different and renamed typhus 
exudatious gallinarium in 1880 (100).  By 1901, the causative agent was shown to be an 
ultra-filterable agent, a virus (22).  The association between the characterized fowl 
plague and other low pathogenic influenza A viruses isolated from birds and mammals 
was not demonstrated until 1955 by Schäfer, when he was able to serologically detect 
type A influenza viral ribonucleoproteins in fowl plague samples (93).     
 Wild aquatic birds are considered the natural reservoirs for type A influenza 
viruses and all type A influenza subtypes have been identified in these species (97, 123).  
Typically, AIV infections in wild waterfowl are asymptomatic, but outbreaks due to 
highly pathogenic avian influenza viruses have been described (55).  AIV can infect 
other avian hosts, such as domestic chickens and turkeys, which can result in large 
economic losses in production and trade (2, 36).  Outbreaks of multiple AIV subtypes 
have affected chickens throughout the years, resulting in depopulation of flocks and loss 
of revenue (43, 45).  Outbreaks of AIV in turkeys have primarily been of the H3, H7, 
and H9 subtypes (45).  Multiple influenza outbreaks have occurred amongst turkeys in 
the United States due to turkey susceptibility to both avian and swine origin influenza 
_________________  
This thesis follows the style of Avian Diseases. 
 2 
viruses (130).  Swine-origin triple reassortant influenza viruses are a common problem 
in turkeys (77, 109).  Pigs can host human, avian, and swine influenza, and are capable 
of generating triple reassortant viruses (59, 127).  Influenza outbreaks in turkeys 
primarily occur in the Minnesota, North Carolina, and Utah due to their close proximity 
to swine operations (45, 54, 71).  This has been a tremendous problem for the turkey 
industry, as they attempt to control the spread of infection while maintaining bird 
numbers and breeder flocks.   
The presence of both low pathogenic avian influenza and highly pathogenic 
avian influenza in poultry flocks has been detected multiple times worldwide in 
domestic poultry farms since 1929 (28, 44, 54, 56).  Highly pathogenic strains cause 
clinical, systemic disease capable of 100% mortality in poultry, while low pathogenic 
strains cause mild to asymptomatic respiratory and enteric tract infections as well as a 
decline in egg production (80).  Low pathogenic strains are more commonly detected 
during AIV outbreaks in domestic chickens and turkeys, however several outbreaks of 
highly pathogenic strains have occurred (44, 106, 107).  As depopulation of the exposed 
flock is often the response to highly pathogenic avian influenza (H5 and H7 subtypes) 
outbreaks, significant economic losses can occur.  This may mean the loss of egg 
production from an entire flock of layers, loss of pounds of broiler meat, loss of breeder 
flocks, and loss of exportation markets for live birds or by-products (43, 91).  
Vaccination is rarely used as a response to chicken AIV outbreaks in the United States as 
it places limitations on trade and exportation.  Importing countries are unwilling to 
accept vaccinated poultry because these birds cannot be differentiated from infected 
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birds (43, 91), but the vaccination strategy has been an increasingly recommended 
method to prevent and control AIV infections in domestic poultry (17). 
1.2. Genome and replication 
 Avian influenza is a type A influenza virus of the Orthomyxoviridae virus family, 
which is characterized by its segmented, negative-sense single-stranded ribonucleic acid 
(RNA) genome.  The Orthomyxoviridae family consists of the Thogotovirus, Isavirus, 
and Influenzavirus A, B, and C genera (80).  Type A influenza viruses are capable of 
infecting avian and mammalian hosts, while types B and C are typically limited to 
mammalian hosts (127).  Influenza virus particles are enveloped and pleomorphic, 
varying in shape from spherical to filamentous (69).  Their genome consists of eight 
negative-polarity RNA segments encoding for 10-12 viral proteins depending on the 
strain.  The three largest segments, segments 1-3, encode for the RNA-dependent RNA 
polymerase complex: polymerase basic 1 and 2 (PB1 and PB2) and polymerase acidic 
(PA), which are required for viral genome transcription and replication.  The 
hemagglutinin (HA) and neuraminidase (NA) are important antigenic determinants and 
are encoded by segments 4 and 6; these two proteins project on the surface of the virus 
particle and are critical for attachment (HA) and release (NA) of the virion.  The fifth 
segment encodes the viral nucleoprotein (74), which interacts with the viral RNA and 
the polymerase complex to form the eight ribonucleoproteins (RNP).  Segment 7 codes 
for two proteins: the matrix protein (M1) which coats the inside of the viral envelope and 
the transmembrane ion channel-like protein (M2) (80).  The eighth segment encodes two 
proteins: the non-structural protein 1 (NS1) and nuclear export protein (NEP), which are 
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important for decreasing host gene expression and exportation of the viral RNPs from 
the nucleus, respectively. 
 Infection begins when the influenza HA protein attaches to its host cell receptor, 
sialic acid (42, 96).  Upon HA-sialic acid binding, the influenza virus enters the cell via 
receptor-mediated endocytosis (58).  Once in the endosome, the M2 ion channel protein 
allows the influx of H+ ions into the virion.  This influx of H+ ions decreases the pH, 
disrupting protein-protein interactions within the virion and leads to the release of viral 
RNP from the M1 protein.  The low pH of the endosomal environment also activates HA 
protein’s fusion properties, leading to fusion of the viral membrane with the endosomal 
membrane, allowing for the release of RNP into the host cell cytoplasm.  Viral RNPs are 
then transported to the nucleus where viral mRNA synthesis and genome replication are 
catalyzed by the viral RNA-dependent RNA polymerase complex, consisting of the viral 
PB1, PB2, and PA proteins. (39).  The viral genome replication occurs by synthesis of 
positive-sense full length copies of viral RNA called complementary RNA (cRNA) and 
subsequent copying of cRNA into negative-sense viral RNA (vRNA).  The synthesis of 
viral mRNA requires host cellular RNA polymerase II because a 5’ capped primer is 
required.  The 5’ capped primer is obtained from newly synthesized host cell mRNA by 
the “cap snatching” mechanisms carried out by the viral polymerase complex (80).  
Translation of the M2, HA, and NA envelope proteins from mRNAs, occur in the rough 
endoplasmic reticulum of the host cell.  These viral envelope proteins produced then 
undergo post-translational modification, pass through the Golgi for additional 
modifications, and are transported to the apical cell surface of polarized epithelial cells.  
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The other viral mRNAs (PB1, PB2, PA, NP, NS1, and M1) are translated on free 
ribosomes and brought back into the nucleus to associate with viral RNAs to form RNPs, 
which are then exported out of the nucleus and through the cytoplasm to associate with 
the envelope proteins.  Once all viral components are present at the apical surface of the 
infected host cell, the viral components assemble into viral particles and release from the 
host cell by budding out of the plasma membrane.  Newly formed viral particles are 
released from the cell surface by NA cleaving of sialic acid, therefore not allowing the 
HA of newly formed influenza virions to become bound and stuck to the surface of the 
host cell from which the virus is being released (80). 
1.2.1. AIV classification 
 Influenza viruses are classified based on their HA and NA surface glycoproteins.  
There currently are 16 HA subtypes (H1-16) and 9 NA subtypes (N1-9), which permits a 
possible 144 different influenza combinations based on HA and NA alone (80).  Avian 
influenza viruses are further classified by virulence by denoting strains as low 
pathogenic avian influenza (LPAI) and highly pathogenic avian influenza (HPAI) (15).  
LPAI is associated with low morbidity and typically do not result in mortality, while 
HPAI strains are defined by their high morbidity and/or mortality in chickens (127).  The 
H5 and H7 AIVs are the only known subtypes capable of becoming HPAI, but not all H5 
and H7 subtypes are HPAI (2).  Pathogenicity testing of AIV can be based either by 
virus challenge in chickens or by sequence analysis (3).  During AIV pathogenicity 
index testing in chickens, if 6-8 out of 8 AIV inoculated chickens die, the virus is 
considered HPAI, but if no birds die during challenge the virus is considered LPAI (3).  
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If 1-5 birds die, the influenza virus is considered moderately pathogenic (3).  Genetic-
based classification of pathogenicity is based on the influenza hemagglutinin (HA) 
cleavage site sequence.  The AIV HA cleavage site is typically cleaved by the exogenous 
protease trypsin, limiting infection to the respiratory and gastrointestinal tracts because 
trypsin in only present at those sites (127).  HPAI contains a polybasic amino acid 
sequence at its HA cleavage site, allowing the AIV to be cleaved by furin-like proteases 
(121).  Furin is ubiquitous throughout the body, allowing for systemic infection of AIV 
containing a polybasic HA cleavage site (127).    
1.2.2. Mechanism of mutations of the AIV genome 
 Genetic mutations in the influenza genome can allow the virus to evade the 
immune system of the host despite prior exposure.  AIV genome changes occur either by 
genetic drift or genetic shift (123).  Genetic drift is the accumulation of point mutations 
during normal viral replication due to the viral RNA polymerase’s lack of proofreading 
mechanism, and is the most common method of change.  These point mutations typically 
result in influenza viruses associated with epidemics, such as seasonal influenza 
infections in humans, as protection developed against the past year’s influenza strain 
may not provide protection against the currently circulating strains.  Genetic shift occurs 
when more than one influenza virus replicates in the same host and in the same cell, 
allowing genome segments to switch between the strains during viral assembly (123).  
This type of genomic mutation is quite rare and is typically how pandemics strains are 
generated, such as the 1957 H2N2 Asian flu pandemic (87, 129), the 1968 H3N2 Hong 
Kong pandemic (87), and the 2009 H1N1 pandemic (99). 
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 AIV infections in the United States’ domestic chickens are typically not a 
problem (123).  Typical commercial poultry operations in the United States do not 
expose their domestic flocks to wild bird reservoirs or practice mixed-species production 
on its facilities, reducing the risk of AIV exposure (44).  Upon transmission into 
chickens, mutations in the AIV genome can allow adaptation of the virus to the chicken 
host (11, 12).  Avian influenza outbreaks do occur on rare occasions in the United States, 
and are typically of low pathogenic strains (44, 54, 56, 126).  Upon survival and passage 
in chicken hosts, AIV genome mutations can produce a HPAI (11, 12, 66).  The standard 
method of response to an AIV outbreak in chickens is culling of the infected flock (107).   
1.2.3. AIV screening in the United States 
 Routine serological screening is the current surveillance method used by the 
poultry industry (118).  As recommended by the United States Department of 
Agriculture’s (118) National Poultry Improvement Plan (74), flocks are screened for 
AIV at 90-day intervals through serological or viral isolation methods by the National 
Animal Health Laboratory Network (NAHLN) (3).  NAHLN laboratories conduct early 
avian influenza surveillance in the United States and have the capacity to screen a large 
number of samples during an outbreak (3).  The agarose gel immunodiffusion assay 
(AGID) is a highly specific test that detects antibodies against the type specific influenza 
antigens NP and M1 and is considered the gold standard serological screening method 
for AIV (74, 118), but results can sometimes be difficult to read and subjective.  The 
hemagglutination inhibition (HI) assay, which detects HA-specific antibodies, is another 
test that can be used to screen for exposure to avian influenza by detecting HA-specific 
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antibodies (118).  The HI assay can also be used for quick HA subtyping to detect 
antibodies produced against the potential HPAI subtypes, H5 and H7 (127).  These 
serological assays are used for routine surveillance because they are both cost effective 
and can be easily used to screen multiple samples.  If H5 or H7 HPAI is suspected in a 
flock, RNA isolation of the influenza virus genome and real-time reverse transcriptase-
polymerase chain reaction (rRT-PCR) targeting the influenza matrix gene is the 
preferred method of diagnosis, followed by pathogenicity testing (3).  Real-time RT-
PCR amplification is a more sensitive assay method because it is able to detect actual 
influenza gene segments.  Because this assay method detects the virus, viral isolation 
and subsequent rRT-PCR testing is the preferred method during or when an AIV 
infection is suspected.  In contrast, AGID is used for routine surveillance because this 
assay detects the production of antibodies against AIV, which occurs after infection.  
Positive rRT-PCR results for influenza in state laboratories must be further tested by 
National Veterinary Services Laboratory (NVSL) in Ames, Iowa to confirm results (3, 
74).  Pathogenicity testing consists of 0.2 mL intravenous injection of 4-8 week old 
naïve birds with 1/10 dilution of the influenza virus sample in bacteria-free allantoic 
fluid and observing mortality rates (3).  Should there be mortality in 6-8 out of 8 birds 
within 10 days after inoculation, the virus is considered highly pathogenic.  If there is no 
mortality, the influenza virus is considered lowly pathogenic.  If the influenza induced 
mortalities between 1-5 out of 8 birds is considered moderately pathogenic (3).  In 
contrast to LPAI, moderately pathogenic AIV can result in mortality rates ranging from 
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5-97%, with the highest mortality in young or stressed birds, as well as cause lesions in 
the respiratory tract and various gastrointestinal organs (19, 137).   
 Confirmatory and pathogenicity testing is particularly important when an AIV 
outbreak occurs, so a suitable response to the outbreak can be quickly implemented.  An 
outbreak of H7N2 AIV occurred in 2003 on a commercial layer farm in Connecticut; 
this virus was classified as LPAI (91).  An approximate 1.3 million layers were in 
production and cost of depopulation was estimated to exceed $30 million by the 
Connecticut Department of Agriculture (91).  To reduce losses, Connecticut opted to 
vaccinate its flocks with inactivated H7N2 influenza vaccine; vaccinating both the 
already infected hens as well as naïve replacement pullets (91).  Due to the 15 months 
length of each layer production cycle, and the time necessary for the farm to maintain a 
zero infection rate, it would take several years for this farm to obtain an AIV-free status.  
In February 2004, an AIV outbreak occurred in a commercial broiler flock with an 
estimated 6,600 birds in Gonzales County, Texas (83).  Birds were tested positive for 
AIV based on initial diagnosis via AGID assay and the virus was identified as an H5N2 
subtype; the H5N2 strain was classified as HPAI based on sequence analysis (83).  
Depopulation of the flock was performed to prevent potential spread of this H5N2 virus, 
but after completion of pathogenicity index testing, no mortality was observed in the test 
birds (83).  Depopulation of the infected flock after the initial HPAI classification was 
necessary to prevent spread of a potentially high pathogenic avian influenza infection, as 
an outbreak response cannot wait for further pathogenicity test results. 
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1.3. Vaccines 
 Transmission of AIV into domestic poultry is economically and politically 
detrimental to the industry; almost 9 billion pounds of broiler meat and 91 billion eggs 
were processed in the United States in 2010 alone (119).  Currently, the United States 
poultry industry does not vaccinate against avian influenza due to the low probability of 
infection and the expense of vaccination.  Currently used AIV-screening assays are 
unable to differentiate between infected and vaccinated birds, which would limit the 
United States’ ability to export its poultry if current vaccines are used (44, 78, 104).  
Other countries without major export markets and endemic AIV infections in their 
domestic poultry have chosen to vaccinate their flocks with inactivated influenza virus 
vaccines (25, 85).  The vaccination strategy has been used in the United States during 
AIV outbreaks in chickens on rare occasions, instead of the usual depopulation strategy 
(43).   AIV inactivated vaccines were used during the 1995 H7N3 AIV outbreak in Utah 
(43), and again during the 2002 H7N2 AIV outbreak in layer chicken breeder flocks in 
Connecticut (91).  In both of these cases, vaccination was able to dramatically reduce the 
expected economic loss by over 50% based in comparison to previous outbreak losses 
and the industry was not forced to cull the entire breeder chicken flock (43).  It is not a 
routine practice to vaccinate turkeys against AIV, but vaccination was used when the 
swine-origin H3 triple reassortant influenza strain infected a turkey flock during an 
outbreak in Minnesota (27).  The use of vaccination decreased mortality amongst the 
birds, but did not become a routine practice in the United States overall (67).  Because of 
their close proximity to swine operations, repeated outbreaks of AIV have occurred in 
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Minnesota and North Carolina turkey operations (45, 130).  Since avian influenza 
vaccination requirements for turkey production are not as strict as vaccination 
requirements in chickens, some commercial producers in the state have opted to 
vaccinate their turkey flocks on a routine basis. 
1.3.1. Inactivated and alive-attenuated vaccines 
 Inactivated/killed vaccines have had moderate efficacy in poultry (79, 112) and 
have been used with great success to prevent many avian diseases affecting the industry.  
The advantages of an inactivated AIV vaccine include uniform levels of immunity, no 
spread of the virus, and little to no adverse reactions (67).  Despite these advantages, the 
current inactivated AIV vaccines induce poor protection in the presence of maternal 
antibodies which would be problematic should breeder hens be vaccinated with 
inactivated AIV vaccines or were naturally infected before lay in countries with endemic 
AIV (32).  In one particular study, chicks carrying anti-H5 AIV maternal antibodies 
were vaccinated with inactivated H5 AIV vaccine and produced lower antibody levels 
compared to chicks without maternal antibodies; these chicks also excreted higher levels 
of HPAI H5N1 virus during challenge (32).  Inoculation with inactivated AIV vaccine at 
one-day-of-age also induced poor protection in chicks with and without maternal 
antibodies based on clinical signs, HI titers, and challenge viral shedding, suggesting 
vaccination with inactivated AIV vaccines at one-day-of-age is ineffective (32).   
 Alternatively, live-attenuated vaccine viruses are able to replicate in the host and 
thus induce strong immune responses (21, 108), but have some drawbacks.  Live-
attenuated vaccines are not approved for use in chickens, because vaccinated chickens 
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are still able to shed the vaccine virus which may regain virulence after passages within 
the chickens (78), but experimental studies have been performed in poultry (21).  Four-
week-old specific pathogen free (SPF) chickens were infected with a laboratory-passage 
attenuated H7N3 AIV to study viral shedding titers and antibody production via HI 
assays compared to the unattenuated H7N3 AIV strain (21).  Reduced viral shedding 
was observed 3 and 6 days post-inoculation in birds vaccinated with the attenuated AIV, 
this strain was also able to induce similar antibody production levels compared to the 
unattenuated strain (21).  Despite the ability to induce high antibody levels, live-
attenuated vaccines have never been seriously considered for commercial poultry use as 
these vaccines are associated with decreased production due to respiratory disease, have 
the potential to revert back to virulence, and can spread from flock to flock (7, 63). 
1.3.2. AIV and DIVA vaccines 
 Avian influenza vaccines currently used are based on inactivated influenza virus.  
A problem with this vaccination strategy is that vaccinated birds cannot be differentiated 
from infected birds with currently used avian influenza detection assays, which would 
limit a country’s ability to trade its poultry with other countries.  The standard AGID 
serological screening assay relies on NP and M1-specific antibody detection (16).  The 
HI assay screens for HA-specific antibodies.  Antibodies against avian influenza HA, 
NP, and M1 proteins would be present in birds vaccinated in the current whole-virus 
inactivated vaccines as well as birds naturally infected with AIV, and therefore both 
vaccinated and infected birds would be positive for AIV using the AGID and HI assays.  
Due to these limitations, countries importing live poultry and poultry products are 
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reluctant to accept poultry immunized with the current inactivated vaccine since these 
birds cannot be differentiated from infected birds (70).  The development of DIVA 
(differentiation of infected and vaccinated animals) strategies in relation to influenza 
vaccines are currently underway and would help resolve some of the issues associated 
with vaccination and screening assays.  Upon successful development of an avian 
influenza DIVA vaccine, AIV endemic countries could vaccinate with fewer concerns 
about trade implications.  Some DIVA strategies involve the use of 1) vaccination with 
homologous HA proteins to the circulating AIV strain, but with a heterologous NA 
protein (5), 2) serological response measurement to NS1 protein (53), or 3) vaccination 
with vectored vaccines (13, 37).  
 Heterologous NA vaccination in birds would allow differentiation of infected 
birds by detecting NA-specific antibody production; vaccinated birds should produce 
antibodies against the recombinant vaccine NA protein, but not the NA of the circulating 
AIV strain.  Naturally infected birds would not develop antibodies against the 
recombinant NA using for vaccination.  The use of heterologous NA vaccination against 
AIV was tested and used in Italy as a response to the H7N1 avian influenza epidemic of 
1999-2000 (18).  This H7N3 vaccine tested for field use was capable of providing 
protection upon challenge with an H7N1 HPAI based on reduced viral shedding as well 
as reduced viremia (presence of infectious AIV in muscles) in chickens (20).  N1-
specific antibodies were detected by indirect immunofluorescent antibody testing using 
recombinant N1 expressing baculovirus (20).  Although vaccination with a homologous 
HA protein and heterologous NA protein may decrease viral shedding and viremia 
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during infection, this vaccination method is not ideal for use in the poultry industry.  
Application of a heterologous NA style vaccine would be effective provided only one 
other NA subtype is circulating at a time in a given area; this is rarely the case in real 
world situations.  If the current circulating/outbreak AIV strain contains the same NA as 
the vaccine, vaccinated and infected birds could not be differentiated, defeating the 
purpose of this DIVA strategy (20). 
Several approaches have been used to develop NS1 deficient vaccines in hopes 
of developing a successful DIVA vaccine.  The NS1 protein, an influenza virus virulence 
factor, interferes with type I interferon responses in the host, decreasing the effectiveness 
of the innate immune response (52, 95).  The NS1 strategy uses absence or presence of 
NS1-specific antibodies to differentiate between vaccinated and infected birds, 
respectively.  One study measured sera NS1-specific antibody levels via enzyme-linked 
immunosorbent assays (ELISA) obtained from AIV infected birds, inactivated 
commercial vaccinated birds, and purified inactivated AIV vaccinated birds.  Birds 
vaccinated with purified inactivated AIV vaccine did not develop antibodies to NS1 
while AIV infected birds possessed high NS1-specific antibodies (116).  Chickens 
vaccinated with unpurified inactivated commercial AIV vaccines possessed low, but 
detectable, levels of NS1-specific antibodies.  Upon challenge infection with a low 
pathogenic AIV, all chickens were able to produce NS1-specific antibodies, but these 
antibody levels rapidly decreased within 5 weeks (4).  The rapid decrease of NS1-
specific antibodies induced by natural AIV infection rendered this DIVA strategy 
ineffective since naturally infected chickens cannot be differentiated from vaccinated 
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birds 5 weeks past the initial time of infection (4, 101).  Commercial scale avian 
influenza vaccine manufacturing for poultry includes non-structural proteins, such as the 
NS1 protein, rendering clear differentiation between vaccinated and infected birds 
impossible.  With this in mind, a vaccination study using a vaccine virus containing a 
mutant NS1, a truncated NS1 without the immunogenic carboxyl end, to differentiate 
between infected and vaccinated birds was conducted (10).  H5N3 AIV infected birds 
produced NS1-specific antibodies, while birds vaccinated with the H5N3 NS1 mutant 
vaccine virus did not produce antibodies against NS1, as the immunogenic region was 
removed in the NS1mutant.  This mutant NS1 vaccine was able to reduce viral shedding, 
based on viral RNA levels, but the NS1 protein regained virulence upon back passage in 
chickens (10).  
Additional DIVA vaccines for AIV have been developed using fowl poxvirus 
(14, 26, 86), Newcastle’s disease virus (88, 94), turkey herpesvirus (64, 89), and 
adenovirus (68, 114) as vaccine vectors for use in poultry.  AIV vaccination using a viral 
vector delivery system allows for dual vaccination, a bivalent vaccine, against both AIV 
and the viral delivery system; this allows birds to develop immunity against the actual 
virus vector used and AIV (120).  Vaccines are already developed against fowlpox, 
Newcastle’s disease virus, and Marek’s disease, but bivalent vaccines capable of 
providing protection against two diseases at once would reduce the amount of vaccines 
administered and reduce vaccination expenses.  Virus vector vaccines have the potential 
for DIVA capabilities.  Vaccinated birds would develop antibodies to only the AIV 
protein included in the bivalent vaccine, but not develop antibodies to any of the other 
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avian influenza virus proteins, such as the NP or M1 proteins.  Because the AGID assay 
used to screen for avian influenza infection targets NP and M1-specific antibodies, 
vaccinated birds would be negative for AIV infection during screening.   
TROVAC-H5, a live recombinant fowlpox vaccine expressing the H5 
hemagglutinin protein, has full registration in Mexico, El Salvador, and Guatemala and 
is licensed for emergency use in the United States (14).  When vaccinated into 1-day-old 
SPF chicks, the TROVAC-H5 vaccine was able to protect against morbidity, mortality, 
and reduce viral shedding upon challenge with H5N2 HPAI 3-weeks after vaccination 
(103).  Protection was conferred up to 20 weeks after vaccination, showing TROVAC-
H5 provided long-lasting immunity.  All vaccinated birds were negative upon AGID 
testing for AIV, showing its potential use as a DIVA vaccine (103).  Another trial using 
fowlpox expressing the H5 protein from H5N1 HPAI was able to induce high HI titers 
after vaccination in 4-week-old SPF chickens, and provide protection against 
homologous challenge 3-weeks post-vaccination based on reduced viral shedding and 
survival of all chickens (86).  Fowlpox-based vector vaccines against AIV are ineffective 
when birds have been previously vaccinated or exposed to fowlpox (102), but are still 
effective in the presence of maternally-derived antibodies (14).   
Attempts have been made to develop bivalent Newcastle’s disease virus vector 
systems for H5 AIV vaccination (37, 75, 120) and H7 AIV vaccination (105).   The 
NDV-H5 vector vaccine was approved for use in China and developed using reverse 
genetics to insert the AIV H5 gene between the NDV matrix and phosphoprotein genes 
of the currently used Newcastle’s vaccine strain, LaSota (37).  Both the NDV-H5 and 
 17 
NDV-H7 vaccines induced protection against both NDV and AIV based on reduced 
mortality upon lethal challenge against NDV and HPAI, and the induction of high HI 
levels compared to unvaccinated chickens (37, 105, 120).  The NDV-H5 live-attenuated 
vaccine was able to induce antibody production and provide protection upon challenge 
with homologous and heterologous H5 AIV subtypes (37, 75).  Although the eye-drop 
inoculation method was the only method used during experimental testing, these 
vaccines may allow for spray inoculation to vaccinate large chicken flocks at once, 
eliminating the need for individual inoculation of birds by trained personnel.  A 
disadvantage to the NDV vector method would be that if the birds have pre-existing 
immunity to the vector delivery system, as the vaccine vector would be cleared before 
successfully inducing an immune response to the AIV protein (94).  This is also true 
when recently hatched chicks contain high levels of maternally-derived antibodies, 
because the vaccine vector again will be cleared from the chicks’ system before inducing 
a protective immune response (32).  Upon vaccination with NDV-H5, SPF chickens 
were protected against both NDV and H6N2 LPAI upon challenge based on reduced 
viral shedding, but turkeys exhibiting anti-NDV maternal antibodies at vaccination time 
had only marginally reduced viral shedding titers (94).  Therefore the NDV vector 
vaccination strategy cannot be used for birds previously vaccinated against NDV, birds 
already naturally infected, or birds with high levels of maternally-derived antibodies. 
Turkey herpesvirus (HVT) has been used to vaccinate chickens against Marek’s 
disease for over 50 years.  Recently, an HVT vector system with an HA insert was 
developed by Ceva for use in avian influenza endemic countries.  Ceva’s Vectormune 
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HVT-AIV vaccine has passed requirements for USDA registration as a genetically-
engineered vaccine (23).  The HVT-AIV vaccine has been shown to be effective in the 
presence of maternally-derived antibodies (31) and provides protection against both 
Marek’s disease and AIV based on reduction of clinical signs and reduced viral shedding 
(in both level of viral excretion and number of shedding birds) (31).  Because 
maternally-derived antibodies do not decrease vaccine effectiveness, the HVT-AIV 
vaccine can be inoculated at one-day-of-age as well as in ovo (24).  Herpesvirus 
infections are life-long and because HVT-AIV is administered as a live vaccine, the 
vaccine-induced immunity is life-long.  Upon homologous challenge with a H7N1 
HPAI, HVT-H7 vaccinated turkeys had reduced viral excretion and reduced mortality 
(64).  Five out of 7 vaccinated birds survived the challenge with H7N1 HPAI, while 
none of the unvaccinated turkeys survived the challenge (64).  When comparing the 
HVT-H5 vaccine with the Ceva-Mexico produced inactivated H5N2 vaccine, HVT-H5 
vaccinated turkeys developed heterologous protection between two antigenically 
different HPAI H5N1 strains circulating in Egypt from 2007 and 2008 (89).  HVT-H5 
vaccinated birds had increased HI titers, no mortality, and reduced viral shedding upon 
challenge (89).  Vaccination with inactivated H5N2 vaccine produced by Ceva-Mexico 
showed only a delay in bird death after challenge with the 2008 Egypt HPAI H5N1 
when compared to unvaccinated turkeys.  Heterologous protection against the 2007 
Egypt H5N1 could not be tested in the inactivated H5N2 vaccinated birds due to bird 
mortality (89). 
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Replication-defective recombinant adenovirus (Ad) has also been successfully 
used as a delivery vector for AIV vaccination (68, 114).  Ocular vaccination of 
commercial layer chickens with adenovirus encoding the H5N9 HA (Ad-H5) at 5 days 
of age and boosted at 15 days produced high levels of H5-specific antibodies at 32 days 
of age based on HI assay (114).  Birds singly vaccinated, without booster, maintained 
antibody levels similar to unvaccinated control birds.  Upon challenge with H5N2 HPAI 
at 42 days of age, no mortality was observed in Ad-H5 boosted birds as well as 
significantly reduced challenge viral shedding based on quantitative RT-PCR (114).  In 
another study using the Ad-H5 vaccine, SPF chickens were vaccinated in ovo at 18 days 
of embryonation and challenged with H5N2 HPAI at 42 days of age (68).  Reduced viral 
shedding was observed via quantitative RT-PCR in vaccinated birds as well as increased 
survival.  Antibody levels were measured via HI assay, showing persistent antibody 
levels up to 18-weeks-of-age.  Chickens without detectable levels of antibody were also 
protected from challenge based on survival and reduced viral shedding (68), supporting 
the recent finding that adenovirus vectors used for AIV vaccines elicit effector and 
memory CD8+ cytotoxic T lymphocytes (98).  Chickens vaccinated in ovo in the 
presence of maternally-derived antibodies did not seroconvert, indicating interference of 
vaccine efficacy in the presence of high levels of maternally-derived antibodies (68). 
1.4. M2 protein and M2e peptide 
1.4.1. M2 protein characterization 
 M2 protein is a conserved protein among influenza A viruses, which 
homotetramerizes to form the transmembrane ion channel necessary for successful viral 
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uncoating and subsequent replication in the host cell (50).  The influenza M2 ion channel 
protein allows an influx of H+ ions into the virion, which breaks protein-protein 
interactions, and allows the viral RNPs to be released into the host cell cytoplasm.  M2 
protein is expressed at low levels on the influenza virion surface and at higher levels on 
infected host cells (60, 132).  Due to M2’s low expression levels on the virus surface, 
natural infection with AIV does not induce a strong M2-specific immune response from 
the host.  Typical immune responses against AIV target the HA protein, resulting in the 
production of neutralizing HA-specific antibodies allowing the host to clear the 
infection, but mutations in the HA protein frequently occur via antigenic drift which can 
render prior subtype-specific immunity ineffective.  Because M2’s coding sequence 
overlaps with the influenza A M1 coding sequence, which is highly conserved, 
mutations rarely occur in the M2 sequence (60).  Based on M2’s highly conserved nature 
amongst influenza A viruses, antibodies against M2 should provide cross-protection 
against different influenza A virus subtypes.  The M2e peptide is the N-terminus 
extracellular epitope of the M2 protein and may be a suitable target for universal avian 
influenza vaccines (60, 132).  Although the mechanism by which M2e-specific 
antibodies act is unclear, mouse studies have shown M2e-vaccines induce type II T 
helper (Th2) cells, activating antibody production, which goes on to opsonize infected 
cells to induce antibody-dependent cytotoxicity or phagocytosis in vivo, thus reducing 
viral production and protecting against full avian influenza infection (34, 51).  M2e-
specific antibodies do not prevent AIV infection from occurring, but are able to provide 
protection based on reduced viral shedding during infection (34, 35, 51). 
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1.4.2. M2e-based vaccines 
 M2e-peptide based vaccines have been designed for many host systems, with 
studies predominantly performed in mice.  Because M2e peptide possesses low 
immunogenicity (9, 51, 125), the peptide must to be inoculated in conjugation with 
highly immunogenic proteins or delivery systems, or be provided in multiple copies in 
order to induce a significant immune response (134).  Most studies have shown M2e-
specific antibodies opsonize infected cells to induce phagocytosis (34, 48, 131).  One 
study states antibody-dependent cytotoxicity occurs via natural killers cells (51), while 
another study refers to the exclusive use of alveolar macrophages for phagocytosis of the 
infected host cell (34).  Whichever mechanism it may be, transfer of M2e-vaccinated 
mouse serum containing M2e-specific antibodies reduced viral shedding, and thus 
provided protection against influenza challenge in mice (35, 115).  Recent studies have 
shown a large involvement from Th2 cells based on the increased levels of interleukin-4 
(IL-4) cytokine secretion in M2e-vaccinated mice (1, 135).  Upon depletion of Th2 cells 
from vaccinated mice, survival rates dropped almost 50% (1).  These results help support 
previous antibody response mechanisms proposed, confirming Th2 cells are necessary to 
activate antibody responses in the host system.  Because M2e-specific antibodies act by 
reducing viral production, not neutralization of the virus, M2e-based vaccine efficacy is 
measured by reduction in viral shedding during infection.   
 Previous influenza M2e-based vaccination studies have had mixed results; M2e 
fused to hepatitis B core proteins has been very successful in mice (76, 133), but did not 
provide protection in swine (47).  Two phase-I human trials have been conducted to test 
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single-epitope vaccine immunogenicity by vaccinating patients and measuring M2e-
specific antibody production levels at various time points after vaccination.  M2e-
specific antibody production was the only indicator for the human phase-I trials, as 
controlled challenge studies cannot be conducted on human participants.  Both human 
trials, using hepatitis B core-M2e fusion from Sanofi Pasteur Biologics (73) or flagellin-
M2e fusion from VaxInnate Corp. (72, 117), were successful in these immunogenicity 
studies.  Several trials have been conducted using multiple epitope vaccines, vaccines 
containing multiple influenza protein epitopes, in order to stimulate cytotoxic T-cell 
involvement.  Dynavax used a combination influenza NP and M2e vaccine in order to 
induce production of both M2e-specific and NP-specific antibodies, which have been 
shown to induce cytotoxic T cell involvement.  This vaccine safely stimulated 
production of antibodies during phase-I human trial. (33).  Biondvax developed an HA, 
NP, and M1 epitope vaccine shown to safely induce both humoral and cell-mediated 
immunity during phase I and II human trials based on production of antibodies and 
activation of cellular immunity by interferon gamma (IFN-γ) and interleukin 2 (IL-2) 
secreting T-lymphocytes (8).   
AIV vaccination trials in chickens have been quite successful.  Salmonella 
expressing an M2e and immune-enhancing CD154 peptide fusion (61) was able to 
induce a strong M2e-specific immune response in chickens.  The Salmonella-M2e 
conjugate vaccine induced M2e-specifc antibody production and provided full protection 
upon challenge with low pathogenic H7N2 AIV based on reduced clinical signs and 
shedding, but not against highly pathogenic AIV.  Another trial vaccinated chickens with 
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a M2e-E. coli maltose-binding protein fusion vaccine (134).  The M2e-fused to E. coli 
maltose-binding protein vaccine was able to reduce mortality rates in chickens upon 
lethal challenge with highly pathogenic H5N1 AIV, providing partial protection against 
AIV.  Both M2e vaccine studies in chickens provided partial to full protection against 
AIV after conjugation with more immunogenic partners, based on antibody production 
levels, reduced morbidity/mortality during challenge and reduced viral shedding.  These 
studies are particularly important because most M2e-based vaccination trials and 
efficacy data are primarily performed in mice, not chickens, which have differing 
immune system mechanisms. 
1.5. Sindbis virus vectors  
Sindbis virus is an Alphavirus of the Togaviridae family, characterized by its 
unsegmented positive-sense RNA genome (40).  The nsP1-nsP4 nonstructural genes are 
encoded at the 5’ end of the viral genomic RNA while the capsid and envelope structural 
proteins are encoded from subgenomic messenger RNA, transcribed from the center of 
the genome and extended to the 3’ end.  The surface of the Sindbis virion is covered by 
propeller-like projections made of the envelope 1 (E1) and envelope 2 (E2) 
glycoproteins.  The E1 and E2 proteins form an E1-E2 heterodimer, which further 
trimerizes to form each surface projection.  With 80 projections on the Sindbis viral 
surface, a total of 240 E1 and 240 E2 proteins are expressed.  Both the Sindbis E1 and 
E2 glycoproteins are highly immunogenic; E1-specific antibodies tend to cross-react 
with other alphaviruses, while E2-specific antibodies are virus specific (i.e. Sindbis 
virus) (40).  As an arbovirus, Sindbis’ transmission cycle alternates between an 
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arthropod vector, in this case the mosquito, and a vertebrate host.  Sindbis is naturally 
inoculated intravenously and replicates in avian species as its vertebrate host.  This 
infection is asymptomatic, causing no clinical morbidity or mortality in the birds and 
would therefore not cause reduced production after vaccination with this vector (40).  
Sindbis virus has also been established as a safe and convenient expression system, 
capable of expressing large numbers of foreign viral proteins fused to its E2 
glycoprotein, and is not considered a significant human pathogen (40).   
1.5.1. Sindbis as a vaccine vector 
 Many vaccines have used Sindbis as a delivery system with effective results (6).  
Sindbis has proven to be a successful vaccine vector against measles by expressing 
measles virus hemagglutinin and fusion proteins, which provided full protection upon 
challenge in rhesus macaques (81).  Another vaccine using Sindbis vector expressing 
glycoprotein G of rabies virus has also been successfully shown to provide protection 
against Rabies infections in dogs (41, 92).  One study used Sindbis to express anthrax’s 
protective antigen as a potential anthrax vaccine (111).  Although this Sindbis-anthrax 
protective antigen vaccine vector was able to induce antibody production, the antibodies 
produced did not provide protection upon challenge with anthrax in mice.  Despite this 
inability to provide protection, the anthrax vaccine was able to enhance the protective 
effects of ciprofloxacin, an antibiotic commonly used to treat anthrax.  Because this 
virus naturally infects avian species (40), Sindbis virus provides an excellent platform 
for avian influenza vaccination in chickens and would allow differentiation between 
vaccinated and infected birds.  
 25 
1.6. E2S1-M2e vaccine vector 
1.6.1. E2S1-M2e design and production 
 A Sindbis virus expressing the M2e peptide was designed and produced at the 
University of Texas at San Antonio (UTSA) in Dr. Hans Heidner’s laboratory.  The 
A/Puerto Rico/8/1934/H1N1 (PR8) M2e peptide gene 
(SLLTEVETPIRNEWGCRCNGSSD) was inserted into the Sindbis genome upstream 
from the E2 glycoprotein gene.  The envelope 3 (E3) gene was removed so the M2e 
peptide became the N-terminus of the E2 protein.  This insertion allowed the PR8 M2e 
peptide to be expressed as a fusion peptide on the surface of each Sindbis E2 envelope 
glycoprotein.  This created a 240 M2e dense Sindbis virus (Fig. 1) without affecting 
viral replication (46).   
 
Fig. 1.  Cryo-electron tomography of parental E2S1 Sindbis virus and recombinant 
E2S1-M2e vaccine virus.  M2e peptides are depicted in blue and fused to the Sindbis E2 
surface glycoprotein.  
 
 
The parental Sindbis virus delivery system used was the E2S1 virus strain; this 
Sindbis virus strain contains genetic alterations made on the E2 glycoprotein gene to 
 26 
allow for expression of fusion peptides (110).  The recombinant virus expressing the 
influenza M2e peptide was designated the E2S1-M2e vaccine virus.  The E2S1-M2e 
virus is expected to easily infect and replicate in birds because avian species are the 
natural host for Sindbis virus infections.  The dense M2e expression on the recombinant 
E2S1-M2e virus should overcome the influenza M2e peptide’s natural low 
immunogenicity and induce a greater immune response in the host.   
1.7. Hypothesis 
 Based on Sindbis virus’ ability to cause asymptomatic infection in avian species 
and the recombinant E2S1-M2e virus expresses a high density of M2e peptides, we 
hypothesized that vaccination of chickens with E2S1-M2e virus will induce the 
production of M2e-specific antibodies and provide protection against AIV upon 
challenge with low pathogenic H5N3 AIV. 
1.8. Objective 
 The specific objective of this study was to evaluate the recombinant E2S1-M2e 
virus as a potential AIV vaccine in chickens, with the long-term objective of developing 
a universal AIV type A vaccine based on the E2S1-M2e system. 
1.9. Significance 
 Introduction of AIV into a poultry flock would have significant economic impact 
on the industry by reducing production rates or requiring depopulation of the flock to 
eliminate spread of the disease.  Currently, the U.S. does not routinely vaccinate its 
chickens against influenza, primarily due to the low probability of AIV transmission into 
chickens makes vaccination not cost effective and the negative trade implications 
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because current inactivated AIV vaccines do not allow differentiation between infected 
and vaccinated animals.  The use of the E2S1-M2e vaccine vector offers the capability to 
differentiate between infected and vaccinated birds while providing universal protection 
against AIV, a major advantage.  A universal avian influenza DIVA vaccine would 
allow the United States to vaccinate its flocks without negatively effecting exportation.   
This vaccine could also be stockpiled for emergency use; because of E2S1-M2e’s 
universal capabilities it can be of immediate use during poultry outbreaks, eliminating 
the time required for new vaccine reformulation, production, and distribution.  
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2. E2S1-M2e VACCINE EFFICACY IN CHICKENS 
2.1. Introduction 
 Avian influenza is a respiratory and enteric disease caused by type A influenza 
viruses of the Orthomyxoviridae virus family (127).  Type A influenza viruses are 
classified based on the two major surface proteins: hemagglutinin (HA) and neuramidase 
(NA); there are 16 HA subtypes and 9 NA subtypes.  Wild waterfowl are the natural 
reservoirs for avian influenza viruses (AIV), but these viruses can infect other non-
natural avian hosts such as chickens, turkeys, or quail (2).  The introduction of AIV into 
a poultry flock would have significant economic impact on the industry by reducing 
production rates or requiring depopulation of the flock to eliminate spread of the disease, 
therefore causing loss of profits and incurring extra expenses during an outbreak (15).   
 The United States does not vaccinate its poultry flocks against avian influenza.  
Current inactivated AIV vaccines do not allow differentiation between infected and 
vaccinated birds by the presently used AIV-screening assays.  Other countries will not 
import United States poultry if the vaccinated birds cannot be distinguished from 
infected birds.  The low probability of AIV transmission into domestic poultry makes 
vaccination against AIV cost ineffective as well.  Existing AIV vaccines provide only 
subtype-specific protection (14, 37), requiring continuous vaccine reformulation and 
production to remain current with the circulating influenza subtype.  Stockpiles of H5 
and H7 AIV subtype vaccines are retained in the United States because these subtypes 
are capable of becoming highly pathogenic, but vaccine stocks of the other 14 HA 
subtypes are not reserved (107).  Should an avian influenza outbreak occur from these 
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other 14 HA subtypes, it would take months to reformulate and distribute a new vaccine.  
The development of a universal stock vaccine providing protection against multiple AIV 
strains, capable of differentiation between infected and vaccinated animals (DIVA), 
would eliminate the need and cost associated with vaccine reformulation, production, 
and distribution.   
The influenza M2 protein is a highly conserved protein necessary for successful 
viral uncoating and replication of influenza A viruses (50, 127).  This protein is 
expressed on avian influenza virions and on the surface of AIV infected cells (60).  
Based on previous studies, the conserved influenza M2e peptide, the M2 protein surface 
epitope, would provide an excellent target for vaccination and cross-protection between 
type A influenza subtypes (61).  Because of M2e’s low immunogenicity, M2e requires 
conjugation with a highly immunogenic protein or delivery system, or vaccination with 
high copy numbers.  The use of a Sindbis virus as a vaccine vector to express the 
influenza M2e peptide would be ideal for use in chickens as this virus naturally 
replicates in avian species causing asymptomatic infections (40), and would allow for 
DIVA strategies.  The vector vaccine developed for use in this study expresses 240 
copies of influenza M2e peptide on the surface of a Sindbis virus (E2S1-M2e).  The 
multiple copies of M2e would induce the development of universal type A influenza 
immunity, while the use of a Sindbis vector permits the use of DIVA strategies to 
differentiate vaccinated and infected chickens.  
The objectives of this study were to determine immunogenicity of the Sindbis-
M2e vector vaccine (E2S1-M2e) in chickens at different inoculation routes and dosages 
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and to determine vaccine efficacy based on reduced viral shedding upon challenge with 
low pathogenic H5N3 AIV.   
2.2. Materials and methods 
2.2.1. Generation of recombinant E2S1-M2e vaccine vector 
 The parental Sindbis virus designated E2S1 (46) and the E2S1-M2e virus were 
designed and developed by Dr. Heidner of UTSA.  The PR8 M2e peptide sequence 
(SLLTEVETPIRNEWGCRCNGSSD) was inserted upstream of the Sindbis E2 gene 
with the E3 gene removed, allowing influenza M2e to be expressed as a fusion peptide 
on the N-terminus of the Sindbis E2 gylcoprotein, resulting in the E2S1-M2e virus.  The 
fusion of M2e to the Sindbis E2 protein did not cause loss of viral infectivity (57) and 
created a virus expressing 240 copies of M2e on its surface.   
2.2.2. Vaccination and challenge 
 Specific pathogen free eggs (Charles River Laboratories International, MA, 
USA) were incubated, hatched in SPF conditions within the laboratory, and moved to 
high-efficiency particulate arresting (HEPA) filtered isolation units for the duration of 
the study.  Chickens were divided in eight different groups with 14 birds/group and 
vaccinated at 4-weeks-of-age.  E2S1 and E2S1-M2e viruses were administered by the 
intranasal or subcutaneous routes, 50 µL and 200 µL respectively, at both high dose (106 
pfu (plaque forming units)) or low dose (103 pfu) per chicken.  Parental E2S1 virus was 
used during vaccination as a control to ensure the parental virus did not produce adverse 
effects in the hosts and to determine background for detection of M2e-specific 
antibodies.  The ninth uninoculated group served as unvaccinated control.  Chickens 
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were boosted two weeks post vaccination using the same dosage and route.  
Subcutaneous and intranasal routes of administration were examined as Sindbis viruses 
infect intravenously by transmission from mosquitos while influenza naturally replicates 
in the respiratory tract (29, 30, 49, 133).  Immunoglobulin A (124) antibodies are 
produced in mucosal surfaces of the respiratory and gastrointestinal tracts while 
immunoglobulin Y (IgY) antibodies is secreted into the blood stream and therefore 
present in vasculated tissue, such as muscle.  Influenza infections naturally reside in the 
respiratory and gastrointestinal tracts; therefore, protection against AIV requires high 
IgA antibody levels.  All groups were challenged with 0.2 mL of 106/mL EID50 (50% 
embryo infective dose) low pathogenic A/Chicken/TX/02 H5N3 AIV two weeks post-
boost by nasal, ocular, and intra-cloana routes.  
2.2.3. Sample collection 
 Blood samples were collected from all chickens at one and two-weeks post-
vaccination and two-weeks post-boost (one day before virus challenge).  Blood (1 mL) 
was collected from the brachial vein and stored at 4°C overnight to allow the serum to 
separate from the red blood cells.  Serum was collected and stored at -20°C until tested.  
Two-weeks post-boost, five birds from each group (4 birds in the control group) were 
euthanized by carbon dioxide asphyxiation and their tracheas collected into 2.5 mL 
phosphate buffered saline (PBS) to determine the presence of M2e-specific IgA 
antibodies.  PBS containing tracheas were stored at 4°C, then vortexed to allow IgA into 
solution and the tracheas then removed from the vials within 5 hours of collection.  
Tubes were then centrifuged and the top 2 mL collected and stored at -20°C until tested.  
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Concentration of some tracheal wash samples was attempted using centrifugal 
microconcentrators (Sartorius Stedim Biotech, Aubagne Cedex, France) following 
manufacturer’s instructions.  Tracheal swabs were collected four days after challenge 
using sterile Dacron swabs (Fisher Scientific, Houston TX, USA) in 2.5 mL tryptose 
phosphate buffer (TPB; Becton Dickinson NJ, USA) supplemented with 
antibiotics/antimycotics [penicillin G (1x104 U/mL), streptomycin (1x104 µg/mL), and 
amphotericin B (25 µg/mL) (Invitrogen, Grand Island NY, USA)].  Samples were stored 
at -80°C until processed for RNA isolation.  Blood samples (1 mL) were collected two-
weeks post-challenge from the brachial vein and process as indicated above.   
2.2.4. M2e-specific IgY and IgA ELISA 
 Serum samples were diluted to 1:50 with PBS and screened for M2e-specific IgY 
antibody levels by enzyme-linked immunosorbent assay (ELISA).  Briefly, Immulon 1B 
medium-binding polystyrene plates (Thermo, TX, USA) were coated with 50 µL total 
volume of 2 µg/mL M2e peptide (Genscript, Piscataway NJ, USA) in carbonate buffer, 
pH 9.6, overnight at room temperature.  The following morning, plates were blocked 
with 250 µL of 3% bovine serum albumin in PBS for 1 hour.  Plates were then washed 
three times with 0.05% Tween 20 in PBS (PBST) using an automated plate washer 
(BioTek ELx50 Microplate Strip Washer, Fisher Scientific) before applying 50 µL of 
1:50 diluted serum sample per well and incubating for 1 hour at room temperature.  
Positive control wells used mouse M2e-specific monoclonal antibody 14C2 (Santa Cruz 
Biotechnology, Santa Cruz CA, USA) against the N-terminus of the M2 protein of the 
A/Wisconsin/1933/H1N1 and was diluted to 1:500 in PBS and used as the primary 
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antibody.  Negative control wells were treated with PBS to check for nonspecific 
binding of secondary antibodies.  Plates were then washed three times with PBST and 50 
µL of 1:10,000 secondary antibody was added to each well followed by one hour 
incubation at room temperature.  Secondary antibody for chicken serum samples was 
horseradish peroxidase (HRP) conjugated goat anti-chicken IgY or IgA (Bethyl 
Laboratories, Montgomery TX, USA) and for mouse HRP-conjugated goat anti-mouse 
Ig H+L (Santa Cruz Biotechnologies, Santa Cruz CA, USA).  After incubation with 
secondary antibody, plates were washed 5 times with PBST, and 50 µL of SureBlue 
TMB substrate (KPL, Gaithersburg MD, USA) was applied for 20 minutes at room 
temperature and optical density values read at 630 nm.  Reactions were then stopped 
with 1N HCl and OD (optical density) values read again at 450 nm.  ELISA was also 
performed on post-boost and post-challenge serum samples using plates coated with 
H5N3 specific M2e peptide (SLLTEVETPTRNGWECKCNDSSD) and following the 
same procedure.  ELISA to determine presence of M2e-specific IgA in trachea washes 
followed the same procedure as IgY, but the sample remained undiluted.  All serum 
samples were tested in triplicate. 
2.2.5. rRT-PCR for viral titer 
 Real-time reverse transcriptase polymerase chain reaction (rRT-PCR) was used 
to calculate viral titers based on the abundance of AIV matrix RNA in chicken tracheal 
swabs collected 4-days post-challenge.  A standard curve was generated using RNA 
extracted from serial ten-fold dilutions of A/turkey/WI/68 H5N9 AIV virus stock of 
known titer, and used to calculate virus titers by extrapolation, as previously described 
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(62).  RNA was extracted from tracheal swab samples using the MagMaxTM-96 Viral 
RNA Isolation Kit (Ambion, Austin TX, USA) following the manufacturer’s protocol, 
and an automated extraction processor (Kingfisher 24, ThermoForma, Inc).  A 1-step 
rRT-PCR, which detects the AIV matrix gene RNA, was performed using AgPath-IDTM 
AIV-M Reagent Kit (Ambion, TX) as per manufacturer’s instructions.   
2.2.6. Hemmagglutinin inhibition assays 
 Hemagglutination inhibition (HI) assays were performed to determine post-
challenge antibody levels against challenge virus.  Serum samples collected post-
challenge were diluted with PBS by two-fold serial dilution up to 1:256.  Twenty-five 
µL of each serum dilution was incubated for 30 minutes with 25 µL of H5N9 AIV 
containing 8 hemagglutinating units.  After 30 minutes incubation at room temperature, 
50 µL of 1% chicken red blood cells (RBCs) was added to each well and HI results read 
45 minutes later.  Virus with only RBCs and virus with negative serum and RBCs were 
used as negative controls.  A chicken anti-H5 virus serum available in our laboratory 
was used as positive control.   
2.2.7. Microneutralization assays 
 To test for M2e-specific neutralizing antibodies, microneutralization assays were 
performed on samples with high M2e-specific IgY OD values.  H5N9 viral titer was 
determined by inoculating confluent monolayers of Madin Darby canine kidney 
(MDCK) cells with ten fold dilutions (8 replicates per dilution) of H5N9 virus stock 
followed by incubation at 37°C in a 5% CO2 atmosphere for 4 days.  Inoculated cells 
were observed daily for presence of cytopathic effect and virus titer calculated using the 
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method of Reed and Muench (90) and expressed as TCID50 (50% tissue culture infective 
dose) units. 
 For the microneutralization assay, serum samples were first incubated with 
receptor-destroying enzyme (Hardy Diagnostics, CA, USA) at 37°C overnight at a 1:3 
ratio respectively to eliminate possible non-specific inhibitors of HA activity in serum.  
The reaction was stopped by 45 minute incubation at 58°C and further diluted to 1:10 
with PBS containing antibiotics/antimycotics.  The 1:10 serum was further diluted (two-
fold dilution up to 1:256) and 50 µL of each dilution incubated with 50 µL containing 
100 TCID50 of H5N9 AIV at 37°C for 30 min.  The serum-virus mixture was then added 
to confluent monolayers of MDCK cells seeded in 96-well plates, incubated for 15 
minutes at 4°C and then transferred to 37°C in a 5% CO2 atmosphere for 45 minutes.  
After inoculation, the serum-virus supernatant was discarded and fresh Viral Production-
Serum-Free Media (Invitrogen, CA, USA) supplemented with antibiotics/antimycotics 
and 1 µg/ml TPCK-trypsin (Invitrogen, CA, USA) added.  Plates were then incubated at 
37°C in 5% CO2 atmosphere for 3 days and 50 µL of the supernatant collected and 
examined for presence of virus by hemagglutination assay.  
 For hemagglutination assay, 50 µL of sample cell culture supernatant or allantoic 
fluid (positive control) was mixed with 50 µL 1% cRBCs, incubated for 45 minutes at 
room temperature and wells examined for presence or absence of hemagglutination 
activity.  Presence of HA activity indicated presence of virus and lack of neutralization 
by the serum sample tested. 
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2.2.8.  Statistical analysis 
 Samples were categorized by virus, route of inoculation, and dosage.  Two-
paired T-tests were used to evaluate mean differences in IgY levels at all time points 
tested, viral shedding, and HI titers between groups.  Spearman correlation coefficients 
were used to compare PR8 M2e-specific IgY with H5N3 M2e-specific IgY levels.  A p-
value <0.05 was considered statistically significant.  Standard deviations for group 
means were calculated at 95% confidence.  Statistical analysis was performed using JMP 
9.0.0 Pro. 
2.3. Results 
2.3.1. M2e-specific IgY antibodies were produced in subcutaneous E2S1-M2e 
experimental groups 
 Thresholds for negative antibody production were calculated based on mean plus 
3 times the standard deviation of the uninoculated control group.  Antibody levels 
greater than the threshold were considered positive for antibody production.  As shown 
in Fig. 2., all parental Sindbis E2S1 vaccinated and unvaccinated control chickens were 
negative for PR8 M2e-specific IgY antibodies at all time points before challenge 
regardless of dose and route of inoculation.  Chickens vaccinated subcutaneously with 
E2S1-M2e at both high and low doses developed statistically significant levels of PR8 
M2e-specific antibodies as early as 1-week post-initial vaccination compared to the 
uninoculated control.   
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Fig. 2.  Pre-challenge PR8 M2e-specific IgY ELISA results.  Mean group M2e-specific 
IgY levels (OD @ 630 nm) are reported for each vaccination group with standard 
deviations at: 1 week (1W) post-vaccination, 2 weeks (2W) post vaccination and 2 
weeks post boost.  The threshold was calculated as mean plus 3 × the standard deviation 
of the uninoculated control group.  Statistically different groups, p-value < 0.05 based on 
paired t-tests, are denoted with (*). 
 
 
Furthermore, the high dose intranasally vaccinated E2S1-M2e group also 
developed statistically significant levels of M2e-specific antibodies vaccination, but to a 
lesser degree than the subcutaneously inoculated experimental groups and only at 2-
weeks post-vaccination and 2-weeks post-challenge.  The low dose intranasal 
experimental group remained negative for M2e-specific antibodies at all times tested 
pre-challenge. 
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2.3.2. M2e-specific IgA antibody levels were not detected  
 Tracheal washes collected pre-challenge (2-weeks post-boost) and post-challenge 
were assayed for M2e-specific IgA antibodies by ELISA.  The IgA ELISA used for 
screening tested positive for ability to bind and detect chicken IgA antibodies.  Results 
for tracheal wash IgA are reported as OD values at 630nm.  As seen in Fig. 3, OD values 
for in all groups, were negative of M2e-specific IgA.   
 
 
Fig. 3.  Pre- and post-challenge PR8 M2e-specfic IgA ELISA results.  ELISA results for 
M2e-specfic IgA in pre-challenge and post-challenge tracheal washes are reported as 
mean OD values at 630nm with standard deviations for each experimental group. 
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Upon sample concentration using centrifugal microconcentrators (Sartorius Stedim 
Biotech, Aubagne Cedex, France), sample OD values remained negative (data not 
shown).  Serum samples pre- and post-challenge were also screened for M2e-specific 
IgA antibodies by ELISA.  Based on OD values at 630nm, samples were also negative 
for M2e-specific IgA (data not shown).  No further IgA analysis was performed. 
2.3.3. M2e-specific IgY antibody levels significantly increased in groups with preexisting 
M2e-specific IgY antibodies after challenge 
 Two weeks after challenge with low pathogenic H5N3 AIV, chickens were bled 
and serum tested for PR8 M2e-specific IgY antibodies by ELISA.  All groups, including 
parental Sindbis vaccinated and uninoculated control, developed PR8 M2e-specific 
antibodies after challenge with low pathogenic H5N3 AIV as determined by ELISA.  
This was expected as the challenge AIV itself contains M2 protein.  A significant boost 
in M2e-specific antibody production was observed in the subcutaneously vaccinated 
groups (low and high dose) as well as the high dose intranasally inoculated group upon 
challenge.  These groups developed statistically significantly higher antibody titers after 
challenge than naïve groups (Fig. 4).  
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Fig. 4.  PR8 M2e-specific IgY levels pre- and post-challenge with low pathogenic H5N3 
AIV.  M2e-specific IgY antibody levels are reported as mean group OD values at 630nm 
for each group at both time points.  Threshold is calculated as mean plus 3 × standard 
deviation of the pre-challenge values of the uninoculated control group.  Error bars 
represent standard deviation.  Mean statistical differences based on paired t-tests with a 
p-value < 0.05 and are denoted with (*). 
 
 
2.3.4. Challenge viral titers were similar in all groups 
 To examine vaccine efficacy, tracheal swabs were collected 4 days after 
challenge and viral shedding measured by real-time RT-PCR using the AgPath-IDTM 
AIV-M Reagent Kit based on influenza virus matrix gene.  Despite high levels of M2e-
specific antibodies in both subcutaneously vaccinated E2S1-M2e groups, there were no 
significant differences in viral shedding between the groups (Fig. 5).  
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Fig. 5. Pre- and post-challenge PR8 M2e-specific IgY levels in comparison to challenge 
virus shedding.  Mean group M2e-specific IgY levels are reported for each group pre-
challenge (2 weeks post-boost) and post-challenge.  Threshold was calculated as mean 
plus 3 × standard deviation of the uninoculated control group and shown as the line at 
the bottom of the graph.  The overlaid line above the bar graph represents mean H5N3 
virus titer of each group 4 days post-challenge and is reported as log viral titers with 
standard deviations.  Mean statistical significance analysis of H5N3 AIV viral shedding 
titers based on paired t-tests with p-values < 0.05. 
 
 
2.3.5. Challenge H5N3 M2e-specific IgY antibodies were detected in pre- and post-
challenge serum samples 
 Cross reactivity of vaccine M2e specific IgY antibodies with M2e peptide from 
H5N3 challenge virus was examined on post-boost and post-challenge serum samples by 
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ELISA.  As seen in Fig. 6, vaccine-induced antibodies recognizing the M2e peptide from 
H5N3 challenge virus were detected in pre-challenge serum for groups with preexisting 
M2e-specific antibody levels from E2S1-M2e vaccination; these levels were statistically 
higher than control groups.  As expected, in groups with negative PR8 M2e-specific IgY 
antibodies levels post-boost, H5N3 M2e peptide binding antibodies were not detected.  
 
Fig. 6. M2e-specific IgY cross reactivity to H5N3 M2e peptide pre-challenge.  Mean 
group M2e-specific IgY levels detected against PR8 and H5N3 M2e peptides are 
reported for each group pre-challenge.  Paired t-tests and Spearman’s correlation 
coefficients with p-values < 0.05 are considered significant.  Statistically significant 
different means are denoted as (*).   
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Although the H5N3 M2e-specific IgY antibodies levels detected were not as high as the 
vaccine M2e-specific IgY antibody levels after challenge, the overall group M2e-
specific antibody levels detected against H5N3 M2e correlate to the PR8 vaccine M2e-
specific antibodies both before and after challenge (Fig. 7).   
 
Fig. 7. M2e-specific IgY cross reactivity to H5N3 M2e peptide post-challenge.  Mean 
group M2e-specific IgY levels detected against PR8 and H5N3 M2e peptides are 
reported for each group post-challenge.  Paired t-tests and Spearman’s correlation 
coefficients with p-values < 0.05 are considered significant.  Statistically significant 
different means are denoted as (*).   
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 Correlation between pre-challenge M2e-specific IgY antibodies detected against 
the vaccine PR8 M2e and H5N3 M2e peptide was statistically significant (p-value 
<0.0001).  Correlation for post-challenge IgY levels was also statistically significant, 
with a p-value of 0.0025.  The antibody detection levels for the H5N3 M2e peptide was 
consistently lower than the PR8 M2e antibody levels, even in the parental E2S1 
vaccinated and uninoculated control groups (Fig. 7).  Low detection sensitivity is 
suspected for the H5N3 M2e ELISA assay, as the mouse monoclonal 14C2 M2e-specific 
antibody control OD values were approximately halved in this assay compared to the 
PR8 M2e ELISA.  Groups without pre-existing PR8 M2e-specific antibody levels before 
challenge should produce higher antibody levels against the H5N3 M2e after challenge.  
2.3.6. Challenge H5N3 AIV successfully infected chickens and induced HA-specific 
antibodies production 
 HI assays were performed on post-challenge serum to test for successful 
infection of H5N3 challenge virus and production of HA-specific antibodies.  Post-
challenge serum was able to bind H5N9 virus in a HI assay and inhibit hemagglutination 
activity of the virus, verifying that AIV was able to infect and replicate in the birds and 
all birds developed H5-subtype specific antibodies (Fig. 8).  No statistical differences in 
HI titers between were observed amongst groups. 
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Fig. 8.  Hemagglutination inhibition (HI) titers of post-challenge serum.  Post-challenge 
serum was diluted by 2-fold serial dilution up to 1:256 and tested for inhibiting 
antibodies.  HI titer is reported as the highest dilution at which hemagglutination 
inhibition occurs.  Mean group HI titers are reported with standard deviations (8-9 
chickens per group).  Mean statistical differences based on paired t-tests p-values < 0.05. 
 
 
2.3.7. M2e-specific IgY antibodies pre-challenge did not neutralize AIV in cell culture 
 Microneuralization assays using H5N9 AIV and MDCK cells were performed on 
pre- and post-challenge serum to test if M2e-specific IgY antibodies were able to 
neutralize AIV.  Both monoclonal mouse IgG against M2e and positive control H5N9 
chicken serum were able to neutralize the virus at all dilutions tested.  As expected, pre-
vaccination serum did not neutralize the virus as chickens were not exposed to the 
 46 
vaccine or avian influenza.  Pre-challenge serum samples from the subcutaneously 
vaccinated E2S1-M2e group with the highest OD values, containing only M2e-specific 
IgY antibodies against influenza, were unable to neutralize the H5N9 virus (data not 
shown).  As expected, post-challenge serum samples, containing M2e-specific as well as 
HA-specific antibodies, were able to neutralize the virus at all dilutions tested.  
2.4. Discussion 
 The use of AIV vaccination, which has not been routinely practiced by the 
United States in the past, is quickly becoming a recommended tool to prevent major 
losses to the poultry industry during AIV outbreaks (17).  Due to international trade 
implications, the use of traditional inactivated AIV vaccines are not feasible in the 
United States as infected birds cannot be distinguishable from vaccinated birds 
serologically.  Although countries in which avian influenza is endemic uses vaccination 
as a method to control AIV in domestic poultry, the traditional inactivated vaccines 
developed are subtype specific (25, 85) and requires reformulation, manufacturing, and 
production when new strains of AIV arise.  
 The objective of this study was to determine whether the E2S1-M2e virus, a 
Sindbis virus vector expressing the PR8 influenza M2e peptide, was a potential 
candidate for a universal DIVA vaccine against AIV by inducing M2e-specific antibody 
production and providing protection upon challenge with low pathogenic H5N3 AIV in 
chickens.  Targeting the influenza M2e peptide enables possible cross-protection 
between different influenza A subtypes due to M2e’s highly conserved sequence (50).  
Expressing influenza M2e on a heterologous virus generates the potential for a universal 
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vaccine with DIVA characteristics, making differentiation between infected and 
vaccinated birds possible (14, 26).  The currently developed HA-based fowlpox, NDV, 
and HVT DIVA vaccines require reformulation and production as new HA subtypes of 
AIV circulate (13, 38).  In contrast to these fowlpox and NDV DIVA vaccines, the 
successful development of an M2e-based DIVA vaccine would potentially provide 
universal immunity against multiple type A influenza strains, and therefore not require 
reformulation for each new outbreak. 
 Upon evaluation in SPF chickens, recombinant E2S1-M2e was able to induce 
high levels of M2e-specific IgY when inoculated by the subcutaneous route.  
Statistically significant levels of M2e-specific antibody production occurred in the high 
dose intranasally inoculated E2S1-M2e groups before challenge (Fig. 3), but levels were 
not as high as subcutaneously inoculated groups.  This may be due to the difference in 
cell trophism between Sindbis virus, which is naturally transmitted by mosquitos 
intravenously, and AIV, which is transmitted by mucosal secretions and naturally infects 
the respiratory and enteric tracts (40, 127).  There is also less control over dosage with 
intranasal vaccination, as birds may swallow the vaccine virus instead of inhaling the 
vaccine into the lungs during inoculation.  An alternative route of inoculation would be 
to intravenously inject the vaccine, as Sindbis is naturally introduced into the host 
system through this route by mosquitos.  Although AIV replicates well in the respiratory 
tract, considering the Sindbis vector delivery system requires intravenous inoculation, 
the vaccine may have had better efficacy had the inoculation route been based on the 
vector delivery system’s replication requirements.  The difficulty with intravenous 
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inoculation is that it would require individual handling of birds and trained personnel.  
Due to the extensive amount of chickens in a commercial setting, individual vaccination, 
especially intravenous inoculation, would be too labor intensive and is not a viable 
option for the poultry industry. 
 The high levels of M2e-specific antibodies induced by both high and low dose 
subcutaneous or high dose intranasal inoculation with E2S1-M2e were not able to 
provide protection upon challenge with low pathogenic H5N3 AIV, measured by rRT-
PCR of viral shedding 4-days post-challenge (Fig. 5), conflicting with previous reports 
using M2e as a vaccine target (61, 113).  Although previously published systems used to 
vaccinate against influenza M2e peptide have had promising results (61, 134), the results 
obtained from this E2S1-M2e study is one of the few in which the M2e-specific 
antibodies were not able to reduce viral shedding during infection (47).  Some studies 
have described protection only against certain pathogenic influenza strains (61), also 
conflicting with the notion that M2e can confer universal influenza A protection.   
 The M2e-specific antibodies induced by E2S1-M2e were not able to neutralize 
AIV in vitro based on microneutralization assays, which was consistent with previous 
reports as M2e-specific antibodies are not known for neutralization (34, 48, 131).  Most 
studies claim M2e-specific antibodies induce protection by opsonizing infected cells 
expressing the M2e peptide to recruit phagocytosis or cytotoxicity of the entire infected 
cell (34, 51).  Although M2e-based vaccines do not prevent influenza infection from 
occurring, M2e-specific antibodies have shown to significantly reduce viral shedding, 
lessening the severity and spread of the disease (134).  Differing to these reports, the 
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mouse monoclonal 14C2 M2e-specific antibody control used was able to neutralize the 
H5N9 AIV in the microneutralization assay (data not shown).  A recent study have 
revealed M2e-specific antibodies may have some neutralization capability (1), stating 
that currently used neutralization assays do not allow adequate time for these antibodies 
to bind the virus since influenza virus expresses very low levels of M2 on its surface.  
The neutralization ability reported from this study was quite low despite the increased 
incubation times, requiring high concentration of the collected mouse serum (1).  In this 
sense, M2e-based vaccines cannot replace inactivated HA-subtype specific vaccines to 
prevent occurrence of influenza infections.  Multiple influenza epitope vaccines may be 
an alternative strategy for vaccination which would allow production of neutralizing 
antibodies by including the influenza HA protein (82) or induction of cytotoxic T cells 
with the use of influenza NP protein epitope (33).  Vaccination of M2e in conjugation 
with other influenza proteins will increase immune responses while M2e provides 
universality and reduces viral shedding.  M2e-specific antibodies induce strong Th2 
responses, which may help strengthen cytotoxic T lymphocyte responses induced by the 
other influenza epitopes overall, generating both a strong humoral and cell-mediated 
immune response.   
 On closer inspection of the M2e peptide amino acid sequences used in this study, 
the PR8 M2e peptide (SLLTEVETPIRNEWGCRCNGSSD) used in the development of 
E2S1-M2e had a five amino acid difference from the low pathogenic H5N3 AIV M2e 
sequence (SLLTEVETPTRNGWECKCNDSSD) used for challenge.  The PR8 M2e 
peptide used in the E2S1-M2e virus was also of mouse-adapted human influenza origin, 
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while the challenge virus used in this chicken trial was an avian influenza virus.  Earlier 
studies have used same origin M2e peptides for vaccination and challenge, i.e. 
vaccination with human influenza M2e peptide and challenge with human influenza, and 
the same with avian influenza studies (113, 128, 134, 136).  This disparity may have 
contributed to the inefficiency of the M2e-specific antibodies induced by the E2S1-M2e 
vaccine.  Despite the 5 amino acid differences, the vaccine-induced M2e-specific 
antibodies recognized and bound the H5N3 M2e peptide before challenge in groups with 
existing vaccine-induced M2e-specific antibody levels.  These results suggest some 
M2e-specific IgY antibody cross-reactivity between the human-origin vaccine PR8 M2e 
peptide and the challenge H5N3 avian influenza M2e peptide, supporting previous work 
that M2e-specific antibodies are cross-reactive in poultry (61, 134).  That PR8 M2e-
specific antibody levels detected were higher than the H5N3 M2e-specific antibodies 
levels, which can be attributed to less sensitivity of the H5N3 M3e ELISA assay.  Less 
sensitivity was determined by the halved OD values detected for mouse monoclonal 
14C2 M2e-specific antibody control in the H5N3 M2e ELISA.  Although these 
antibodies were cross-reactive, viral titers of the experimental vaccinated groups were 
not statistically different from the uninoculated control group (Fig. 5), suggesting the 
antibody-dependent cytotoxicity mechanism did not transpire (34, 51) or a strong Th2 
response was lacking.  Based on this study’s results, the E2S1-M2e vector vaccine 
would not provide universal protection against AIV type A viruses in chickens.  
 For this study, the genetic differences within the M2e regions may not allow for 
cross-protection between influenza A viruses.  M2e is more conserved amongst human 
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influenza strains than avian influenza strains, which may not permit the use of M2e 
peptide as a target for universal vaccination against avian influenza (65).  With this in 
mind, human M2e-based vaccines against avian influenza may not be effective due to 
the less conserved nature of AIV’s M2e peptide.  Twenty-one new M2e variants have 
been found with the majority of the mutations at the center of the peptide (122).  This 
needs to be taken into consideration during M2e universal vaccine development as M2e 
sequence changes may affect immunity.  To further test the worth of M2e as a target for 
universal vaccination, another recombinant E2S1-M2e using an M2e peptide identical to 
the M2e of the avian influenza challenge virus should be developed to test for direct 
protection.  If identical M2e peptides are necessary to provide protection against AIV 
based on reduced viral shedding, M2e may not be a viable target for universal type A 
vaccination.  
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3. SUMMARY 
 
 Chickens were vaccinated with parental E2S1 Sindbis virus or recombinant 
E2S1-M2e virus vector as a potential universal DIVA vaccine against avian influenza A. 
Vaccination with E2S1-M2e vector vaccine induced production of vaccine M2e-specific 
IgY antibodies when subcutaneously inoculated at both dosages.  The intranasally 
inoculated E2S1-M2e group was able to produce some vaccine-induced M2e-speicific 
antibodies, but only at high dose.  Upon challenge with low pathogenic H5N3 AIV, no 
significant difference in viral shedding was observed between any of the groups. HI 
results show the H5N3 challenge virus was able to successfully infect the chickens and 
induce the production of HA-specific antibodies.  High M2e-specific IgY antibodies 
from pre-challenge subcutaneously-inoculated serum samples were not able to neutralize 
avian influenza virus upon microneutralization assay.  Vaccine M2e-specific IgA 
production in all bird groups were negative at both pre- and post-challenge time points.  
Challenge H5N3 AIV M2e-specific IgY antibodies were detected in groups with pre-
existing vaccine M2e-specific IgY antibodies before challenge, suggesting M2e-
antibody cross-reactivity.  All groups developed H5N3 M2e-specific IgY antibodies 
after challenge with H5N3 AIV, but groups with pre-existing M2e-specific antibody 
levels developed higher levels of both PR8 and H5N2 M2e-specific antibodies.  
Although the E2S1-M2e vaccine vector is able to induce the production of M2e-specific 
IgY antibodies capable of cross-reacting in the chicken when subcutaneously inoculated, 
these antibodies are unable to neutralize AIV or provide protection upon challenge with 
low pathogenic H5N3 AIV. 
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